AstraZeneca Pharmaceuticals LP
NEWS
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
AstraZeneca has a problem. Not with its pipeline, but with the way a significant chunk of shareholders views its executive pay program.
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
The third time is the charm for AstraZeneca and its hyperkalemia treatment that has been dogged by manufacturing issues. After multiple rejections, the U.S. Food and Drug Administration finally gave its approval for the treatment.
Emulate, Inc. struck a deal with pharma giant AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization.
AstraZeneca and its biologics research-and-development arm, MedImmune, indicated that its Fasenra (benralizumab) did not meet its primary endpoint in patients with moderate to very severe COPD.
Changes continue at the c-suite level of GlaxoSmithKline. This week another high profile executive, Chief Financial Officer Simon Dingemans announced he will retire from GSK in 2019.
Some accelerators come out of government and academic institutions, while others have specific big pharma backing. Many use a combination of all of the above, while some are private in nature linked to venture capital firms. Let’s look at some of the accelerators linked to big pharma.
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
JOBS
IN THE PRESS